Clinical Trial Update: Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) [Phase 3]

View source ↗

Summary

The Phase 3 PERSEUS trial of the BTK inhibitor tolebrutinib (SAR442168) for primary progressive multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Tolebrutinib (SAR442168) (Tolebrutinib)

Snippet

Sponsor: Sanofi | Conditions: Primary Progressive Multiple Sclerosis | Phase 3 | Status: COMPLETED